<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ATROPINE SULFATE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ATROPINE SULFATE</h1>

        <p><a href="../drugClass/PHP34553.html">ANTIMUSCARINICS (EYE)</a><a href="../drugClass/PHP34659.html">ANTIMUSCARINICS (SYSTEMIC)</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#lessSuitableForPrescribing" data-toggle="tab">Less suitable for prescribing</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Cycloplegia</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye using eye drop</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Anterior uveitis</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye using eye drop</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bradycardia due to acute massive overdosage of beta-blockers</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                3 mg.</li>
              <li class="dose child"><strong>For children </strong><br/>
                40 micrograms/kg (max. per dose 3 mg).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of poisoning by organophosphorus insecticide or nerve agent (in combination with pralidoxime chloride)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                2 mg every 5&#8211;10 minutes until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished, frequency of administration dependent on the severity of poisoning.</li>
              <li class="dose child"><strong>For children </strong><br/>
                20 micrograms/kg every 5&#8211;10 minutes (max. per dose 2 mg) until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished, frequency of administration dependent on the severity of poisoning.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.6&#8211;1.2 mg daily, dose to be taken at night.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Premedication</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous injection or by intramuscular injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300&#8211;600 micrograms, to be administered immediately before induction of anaesthesia.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                300&#8211;600 micrograms, to be administered 30&#8211;60 minutes before induction of anaesthesia.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                300&#8211;600 micrograms, to be administered immediately before induction of anaesthesia.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                300&#8211;600 micrograms, to be administered 30&#8211;60 minutes before induction of anaesthesia.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Intra-operative bradycardia</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                300&#8211;600 micrograms, larger doses may be used in emergencies.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                300&#8211;600 micrograms, larger doses may be used in emergencies.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Control of muscarinic side-effects of neostigmine in reversal of competitive neuromuscular block</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.6&#8211;1.2 mg.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                0.6&#8211;1.2 mg.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Excessive bradycardia associated with beta-blocker use</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.6&#8211;2.4 mg every hour in divided doses (max. per dose 600 micrograms).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bradycardia following myocardial infarction (particularly if complicated by hypotension)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms every 3&#8211;5 minutes; maximum 3 mg.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Not known to be harmful; manufacturer advises caution.</p>
            </section>
      </section>




      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
        
            <section class="advice">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph> in children</h3>
              <p>Toxic systemic reactions can occur in neonates and children.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Systemic side-effects can occur, particularly in children and the elderly.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>For administration <i>by mouth</i>, injection solution may be given orally.</p>
            </section>
      </section>



      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <p>Antimuscarininc drugs used for premedication to general anaesthesia should only be administered by, or under the direct supervision of, personnel experienced in their use.</p>
            </section>
      </section>



      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
                <p class="title">Control of muscarinic side-effects of neostigmine in reversal of competitive neuromuscular block</p>
              <p>Since atropine has a shorter duration of action than neostigmine, late unopposed bradycardia may result; close monitoring of the patient is necessary.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph> in children</h3>
              <p>Not licensed for use in children for uveitis.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in children</h3>
              <p>Not licensed for use by oral route.</p><p>Not licensed for use in children under 12 years for intra-operative bradycardia or by intravenous route for premedication.</p><p>Not licensed for the control of muscarinic side-effects of edrophonium in reversal of competitive neuromuscular block.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Although multi-dose atropine sulphate eye drops commonly contain preservatives, preservative-free unit dose vials may be available.</p>
            </section>
      </section>



      <section class="tab-pane" id="lessSuitableForPrescribing">
        <h2>Conditions when less suitable for prescribing</h2>

            <section class="lessSuitableForPrescribing">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in adults</h3>
              <p>Atropine tablets less suitable for prescribing. Any clinical benefit as a gastro-intestinal antispasmodic is outweighed by atropinic side-effects.</p>
            </section>
      </section>




      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <h3 class="specificity">With <ph outputclass="route">intramuscular</ph> use or <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">subcutaneous</ph> use</h3>
              <p>Prescription only medicine restriction does not apply where administration is for saving life in emergency.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ATROPINE SULFATE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            eye drops,
            solution for injection,
            oral suspension,
            solution for infusion,
            oral solution,
            eye ointment,

            <div id="PHP74804"><a href="../medicinalForm/PHP74804.html" data-target="#PHP74804" data-action="load">Tablet</a></div>
            <div id="PHP75069"><a href="../medicinalForm/PHP75069.html" data-target="#PHP75069" data-action="load">Solution for injection</a></div>
            <div id="PHP75143"><a href="../medicinalForm/PHP75143.html" data-target="#PHP75143" data-action="load">Eye drops</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
